Navigation Links
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
Date:10/23/2007

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.

"We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market," said Yuval Cohen Ph.D., President of Morria.

"There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria's drug platform could potentially offer such an alternative," said Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known but previous
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Malvern initiates European user group meetings for chemical imaging
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... NEW YORK, Dec. 1 WebMD ...of health information, today announced the honoree...th annual WebMD Health Heroes honor Americans with...severance, who lead an effort to help others achie...ewscom.com/cgi-bin/prnh/20091201/NY18114 ) ,, ...
(Date:12/1/2009)..., MORRISVILLE, N.C., Dec. 1 nConta...vestigation of devices for minimally-invasive trea...itiation of a feasibility clinical trial designed ...surgical and catheter procedure, the convergent pr...al atrial fibrillation (AF). This prospective, fe...
(Date:12/1/2009)..., CHICAGO, Dec. 1 At this year,s ...h America (RSNA), Royal Philips Electronics ( PHG,...space, a set of solutions that provides radiologis...ges at one workspot to help drive quality and effi... Philips will also highlight new capabilities for ...
Breaking Medicine Technology:WebMD Announces 2009 Health Heroes 2WebMD Announces 2009 Health Heroes 3nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4SIRO Clinpharm Collaborates with Mediscis Broadens Early Phase Drug Development Expertise 6344 1SIRO Clinpharm Collaborates with Mediscis Broadens Early Phase Drug Development Expertise 6344 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 1Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 5Highlights of NHLBI supported research presented at American Heart Associations Scientific Sessions 61539 1Highlights of NHLBI supported research presented at American Heart Associations Scientific Sessions 61539 2Highlights of NHLBI supported research presented at American Heart Associations Scientific Sessions 61539 3Highlights of NHLBI supported research presented at American Heart Associations Scientific Sessions 61539 4Highlights of NHLBI supported research presented at American Heart Associations Scientific Sessions 61539 5Highlights of NHLBI supported research presented at American Heart Associations Scientific Sessions 61539 6
... today launched a web-based stroke education and a...ional football player who suffered a stroke in Feb... his career. The unique online educational program... on the AGA Medical website that describe Tedy,s f...nd prevention champion. , , "I hope that by shari...
...d Non-invasive Test Procedure , , MINEOLA, N.Y., ...nt step in the development of an improved first an...screening test to detect Down syndrome and other g...nary study results at the 29th annual Society for ...at indicate a potential breakthrough in testing qu...
Other Medicine Technology:AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi 2AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi 3Breakthrough in Prenatal Screening for Down Syndrome 2
(Date:12/1/2009)... , SACRAMENTO, Calif., Dec. 1 ...d Kaiser Permanente is being hailed as a care deli...will be inducted today into The California Hall of...r Stark, will accept the Spirit of California meda...emony in Sacramento this evening. ,, Kaiser,s ...
(Date:12/1/2009)...eliminary research suggests that criteria based on...mors from colorectal liver metastases after chemot...ntial to predict overall survival, according to a ...addition of bevacizumab to cytotoxic (toxic to cel...val in patients with stage IV colorectal cancer an...
(Date:12/1/2009)... , NEW ORLEANS, Dec. 1 /PRNewswire-USNewsw...the world,s largest professional association of bl...s at the 51st ASH Annual Meeting from December 5-8...in New Orleans, LA. The meeting will showcase the .... ,, "It is my pleasure to host ASH,s 51st ann...
(Date:12/1/2009)... , SOUTHFIELD, Mich., Dec. 1 /PRNewswire-Firs...YSE: FMR ) ("First Mercury" or the "Company") an...of Directors declared a quarterly cash dividend of... shareholders of record at the close of business o...Financial Corporation ,, First Mercury Financi...
(Date:12/1/2009)...urges H1N1 vaccination because pandemic,s course r... (HealthDay News) -- A U.S. health official said T... on the wane nationally, but many experts agreed t..., The flu is now widespread in 32 states -- dow...ieden, director of the U.S. Centers for Disease Co...
Breaking Medicine News(10 mins):Health News:Health Care Pioneer Henry J. Kaiser Inducted Into The California Hall of Fame 2Health News:Health Care Pioneer Henry J. Kaiser Inducted Into The California Hall of Fame 3Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care 2Health News:51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care 3Health News:Swine Flu Waning, But Could Return 2Health News:Swine Flu Waning, But Could Return 3
...s to Impose Pay System Based on Favoritism, WASHI...nt, Washington rallied today to urge the giant med...gnificant sacrifices workers,have made to help Ame...," workers,rallied outside AmerisourceBergen,s Ken...
...sh., Sept. 27 Even for Non Media types, its,hard ...d tabloids a lot,lately and from all indications, ...ar. On a positive note however, a patient came in...brity stars and right,on top of that pile was ... ...
...d Number of AIDS-Related Deaths Continued to Decli...,and federal inmates who were HIV infected or had ...se from 22,936 at the end of 2004, the Justice,Dep... 25,807 state and federal inmates who were HIV inf...
...ept. 27 NuVasive, Inc. (Nasdaq:,NUVA), a medical ...minimally disruptive surgical treatments for the s...d quarter 2007 earnings announcement, which,will t...p.m. ET / 4:00 p.m. CT to discuss the results. The...
...now under Isis, ownership in preparation for partn...ticals, Inc. (Nasdaq: ISIS ), today announced its... at the pre-negotiated price of $120,million. Prom... company, to discover, develop and commercialize u...
...Calif., Sept. 27 The following was released,today..."study" released Wednesday by Death with Dignity N...) board member Margaret Peggy Battin,attempts to s...attin,s twenty-year plus record pro-assisted suici...
Other Medicine News:Health News:AmerisourceBergen Workers Rally For Better Working Conditions 2Health News:HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005 2Health News:HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005 3Health News:NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results 2Health News:NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results 3Health News:Isis Acquires Symphony GenIsis 2Health News:Isis Acquires Symphony GenIsis 3Health News:Californians Against Assisted Suicide: Assisted Suicide 'Study' From Biased Author is Questionable at Best 2
...ermal cycler can do for your laboratory. It featur...ace, and best of all, direct upgradability to real... will raise your expectations of what a thermal cy...er Features:, , Graphical representation of...
...compact thermal cycler. In addition to its speed a...sonal offers first-rate operational flexibility. I...modate 25 x 0.2 ml tubes, 16 x 0.5 ml tubes, or mi...ycler and the Mastercycler gradient, the Mastercyc...
RoboCycler® RS232 Option
... filter wheels with your choice of five (5) filter...n I (492nm-516nm), HEX/JOE/VIC (535nm-555nm), ROX/... (545-568). The system includes notebook computer,...software, User's Manual, Introduction to QPCR Guid...
Medicine Products: